登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由河北医科大学第四医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06681285,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 9
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(9 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Patients with recurrent/metastatic esophageal squamous cell carcinoma were confirmed by pathology or cytology.
入选标准第 2 条
Normal thyroid function is defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled;
入选标准第 17 条
Any of the following situations occurred during previous PD-1 inhibitor treatment:
排除标准第 11 条
Previous occurrence of grade 3 or higher immune-related adverse events(irAE )(excluding endocrine system related irAE) resulting from PD-1 inhibitor therapy, irAE resulting in permanent discontinuation of therapy, grade 2 immune-related cardiotoxicity, or neurological or ocular irAE of any grade.
排除标准第 12 条
Eastern Cooperative Oncology Group(ECOG) score 0-2 points;
入选标准第 4 条
Hemoglobin (Hb) ≥ 90g/L;
入选标准第 9 条
Neutrophil count (ANC) ≥ 1.5 × 109/L;
入选标准第 10 条
Platelet count (PLT) ≥ 100 × 109/L;
入选标准第 11 条
Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 ULN; If there is liver metastasis, ALT and AST should be ≤ 5ULN;
入选标准第 13 条
Total bilirubin (TBIL) ≤ 1.5ULN;
入选标准第 14 条
Serum creatinine (Cr) ≤ 1.5ULN or creatinine clearance rate (CCr) ≥ 60ml/min;
入选标准第 15 条
International normalized ratio (INR) ≤ 1.5, activated partial thromboplastin time (APTT) ≤ 1.5 times ULN;
入选标准第 16 条
According to the solid tumor efficacy evaluation criteria (RECIST version 1.1), there is at least one radiographically measurable lesion;
入选标准第 6 条
Any other malignancies developed during the first 3 years of study, except locally treatable and cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, breast ductal carcinoma in situ, and papillary thyroid cancer
排除标准第 5 条
human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis (hepatitis B, defined as HBV-DNA≥1000 copies /ml; Hepatitis C, defined as HCV-RNA above the lower detection limit of analytical methods) or co-infection with hepatitis B and hepatitis C;
排除标准第 6 条
Women of childbearing age should agree to use contraceptive measures (such as intrauterine devices, birth control pills, or condoms) during the study period and within 6 months after the end of the study; Within 7 days prior to enrollment in the study, the serum or urine pregnancy test must be negative and the patient must be non lactating; Men should agree to use contraception during the study period and for 6 months after the end of the study period for patients
入选标准第 20 条
Pregnant or lactating women;
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06681285,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up; Patients with recurrent/metastatic esophageal squamous cell carcinoma were confirmed by pathology or cytology. Age≥18 years old, male or female; Eastern Cooperative Oncology Group(ECOG) score 0-2 points; Patients who have not received systematic treatment for recurrent/metastatic esophageal squamous cell carcinoma or have received systematic treatment failure for recurrent/metastatic esophageal squamous cell carcinoma; According to the solid tumor efficacy evaluation criteria (RECIST version 1.1), there is at least one radiographically measurable lesion; Expected survival time ≥3 months; There is sufficient organ and bone marrow function, as follows: Hemoglobin (Hb) ≥ 90g/L; Neutrophil count (ANC) ≥ 1.5 × 109/L; Platelet count (PLT) ≥ 100 × 109/L; Serum albumin (ALB) ≥ 30g/L; Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 ULN; If there is liver metastasis, ALT and AST should be ≤ 5ULN; Total bilirubin (TBIL) ≤ 1.5ULN; Serum creatinine (Cr) ≤ 1.5ULN or creatinine clearance rate (CCr) ≥ 60ml/min; International normalized ratio (INR) ≤ 1.5, activated partial thromboplastin time (APTT) ≤ 1.5 times ULN; Normal thyroid function is defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled; The myocardial enzyme spectrum is within the normal range (simple laboratory abnormalities that are deemed clinically insignificant by the researchers are also allowed to be included); Echocardiographic evaluation: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%); Women of childbearing age should agree to use contraceptive measures (such as intrauterine devices, birth control pills, or condoms) during the study period and within 6 months after the end of the study; Within 7 days prior to enrollment in the study, the serum or urine pregnancy test must be negative and the patient must be non lactating; Men should agree to use contraception during the study period and for 6 months after the end of the study period for patients排除标准:Exclusion Criteria:
Patients with uncontrolled or symptomatic active central nervous system (CNS) metastases (patients with CNS metastases who have been adequately treated, are clinically stable for at least 2 weeks, and have stopped corticosteroids 1 week prior to enrollment can be enrolled, and patients with asymptomatic BMS who do not require treatment can be enrolled); There is pleural or peritoneal effusion or pericardial effusion that cannot be controlled after effective treatment; Patients with serious concurrent diseases, such as heart failure, high-risk uncontrolled arrhythmias, severe myocardial infarction, refractory hypertension, renal failure (CKD-stage 4 and above), thyroid insufficiency, mental illness, diabetes, severe chronic diarrhea (more than 7 defecation times per day), etc., and who are deemed unsuitable for participation in this clinical study by the researchers; The presence of any active, known or suspected autoimmune disease. Admitted subjects who are in a stable state and do not require systemic immunosuppressive therapy; Any other malignancies developed during the first 3 years of study, except locally treatable and cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, breast ductal carcinoma in situ, and papillary thyroid cancer human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis (hepatitis B, defined as HBV-DNA≥1000 copies /ml; Hepatitis C, defined as HCV-RNA above the lower detection limit of analytical methods) or co-infection with hepatitis B and hepatitis C; Imaging during the screening period showed that the tumor surrounded or invaded important blood vessels or organs (such as the heart and pericardium, trachea, aorta, superior vena cava, etc.) or had obvious necrosis and voids, and the researchers determined that entering the study would cause bleeding risk; Subjects at risk for esophagotracheal or esophagopleural fistula; Past or current non infectious pneumonia/interstitial lung disease (including radiation pneumonitis) requiring systemic corticosteroid therapy; Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; Individuals who are allergic to the drugs or their components used in this program; Any of the following situations occurred during previous PD-1 inhibitor treatment: Previous occurrence of grade 3 or higher immune-related adverse events(irAE )(excluding endocrine system related irAE) resulting from PD-1 inhibitor therapy, irAE resulting in permanent discontinuation of therapy, grade 2 immune-related cardiotoxicity, or neurological or ocular irAE of any grade. Prior to screening in this study, all adverse events treated with prephase PD-1 inhibitors had not been fully resolved or had not been resolved to grade 1. Subjects with grade 2 or greater endocrine adverse events were admitted if their condition was stable and asymptomatic with appropriate alternative therapy. Prior adverse events requiring immunosuppressant therapy other than glucocorticoids, or recurrent adverse events during prior immunotherapy requiring systemic glucocorticoid therapy; Pregnant or lactating women; with a history of psychiatric drug abuse and can not quit or patients with mental disorders; The researcher thinks that it is not appropriate to participate in this researcher; 15, unwilling to participate in the study or unable to sign the informed consent
引自 ClinicalTrials.gov, NCT06681285, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06681285,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。